中华生物医学工程杂志
中華生物醫學工程雜誌
중화생물의학공정잡지
CHINESE JOURNAL OF BIOMEDICAL ENGINEERING
2008年
5期
374-376
,共3页
李传行%黄子林%吴明玮%张福君%黄金华%范卫君%吴沛宏
李傳行%黃子林%吳明瑋%張福君%黃金華%範衛君%吳沛宏
리전행%황자림%오명위%장복군%황금화%범위군%오패굉
化学栓塞%治疗性%肝肿瘤%黑色素瘤抗原%经导管肝动脉化疗栓塞%病理学%临床%疗效评估
化學栓塞%治療性%肝腫瘤%黑色素瘤抗原%經導管肝動脈化療栓塞%病理學%臨床%療效評估
화학전새%치료성%간종류%흑색소류항원%경도관간동맥화료전새%병이학%림상%료효평고
Chemoembolization,therapeutic%Liver neoplasms%Melanoma antigen%Transcatheter hepatic arterial chemoembolization%Pathology,clinical%Therapeutic effect evaluation
目的 探讨经导管肝动脉化疗栓塞(TACE)对肝癌患者外周血黑色素瘤抗原1(MAGE-1)mRNA表达水平的影响.方法 采用巢式RT-PCR方法 测定18例肝癌患者TACE治疗前后外周血MAGE-1 mRNA的表达.分析其与肝癌临床病理特征间的关系.结果 18例肝癌患者治疗前外周血MAGE-1 mRNA表达10例阳性、8例阴性;TACE治疗后11例阳性、7例阴性.治疗前后外周血MAGE-1mRNA阳性率差异无统计学意义(55.6%比61.1%.P>0.05).治疗前后肝癌患者外周血MAGE-1mRNA阳性率与肿瘤TNM分期((0%比76.9%,20%比76.9%,P<0.05)、远处转移有关(85.7%比36.4%,100%比36.4%,P<0.05),而与肿瘤大小、血清AFP无关(P>0.05).结论 TACE治疗肝癌不会促进肿瘤的血源性转移,MAGE-1 mRNA可作为评估肝癌疗效的一个重要指标.
目的 探討經導管肝動脈化療栓塞(TACE)對肝癌患者外週血黑色素瘤抗原1(MAGE-1)mRNA錶達水平的影響.方法 採用巢式RT-PCR方法 測定18例肝癌患者TACE治療前後外週血MAGE-1 mRNA的錶達.分析其與肝癌臨床病理特徵間的關繫.結果 18例肝癌患者治療前外週血MAGE-1 mRNA錶達10例暘性、8例陰性;TACE治療後11例暘性、7例陰性.治療前後外週血MAGE-1mRNA暘性率差異無統計學意義(55.6%比61.1%.P>0.05).治療前後肝癌患者外週血MAGE-1mRNA暘性率與腫瘤TNM分期((0%比76.9%,20%比76.9%,P<0.05)、遠處轉移有關(85.7%比36.4%,100%比36.4%,P<0.05),而與腫瘤大小、血清AFP無關(P>0.05).結論 TACE治療肝癌不會促進腫瘤的血源性轉移,MAGE-1 mRNA可作為評估肝癌療效的一箇重要指標.
목적 탐토경도관간동맥화료전새(TACE)대간암환자외주혈흑색소류항원1(MAGE-1)mRNA표체수평적영향.방법 채용소식RT-PCR방법 측정18례간암환자TACE치료전후외주혈MAGE-1 mRNA적표체.분석기여간암림상병리특정간적관계.결과 18례간암환자치료전외주혈MAGE-1 mRNA표체10례양성、8례음성;TACE치료후11례양성、7례음성.치료전후외주혈MAGE-1mRNA양성솔차이무통계학의의(55.6%비61.1%.P>0.05).치료전후간암환자외주혈MAGE-1mRNA양성솔여종류TNM분기((0%비76.9%,20%비76.9%,P<0.05)、원처전이유관(85.7%비36.4%,100%비36.4%,P<0.05),이여종류대소、혈청AFP무관(P>0.05).결론 TACE치료간암불회촉진종류적혈원성전이,MAGE-1 mRNA가작위평고간암료효적일개중요지표.
Objective To evaluate the effect of transcatheter hepatic arterial chemoembolization (TACE) on melanoma antigen-I (MAGE-I) mRNA expression in peripheral blood of patients with hepatoceltular carcinoma(HCC). Methods RT-PCR was used to detect MAGE-1 mRNA expression in peripheral blood of 18 patients with HCC before and after TACE. The relationship between the positive rate of MAGE-1 mRNA and pathological characteristics was examined. Results Before TACE treatment, peripheral blood positive MAGE-1 mRNA was detected in 10 patients with HCC, and negative MAGE-1 mRNA in the other 8 patients. After TACE treatment, positive expression of MAGE-1mRNA was detected in peripheral blood of 11 patients, and negative in the other 7 patients. The positive rate of MAGE-1mRNA expression was not significantly different before and after TACE treatment (55.6% vs 61.1%, P >0.05). Before and after TACE,the positive rate was associated with the TNM clinical stages (0% vs 76.9%, 20% vs 76.9%, P <0. 05) and extrahepatic metastasis (85.7% vs 36. 4%, 100% vs 36. 4%, P < 0. 05), and was not associated to the tumor size and serum AFP (P > 0. 05). Conclusions TACE may not lead to hematogenous dissemination in the treatment of HCC patients. The expression of MAGE-1mRNA may be used as a marker for evaluating the efficacy of HCC.
